A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements

被引：64

作者：

Burkett, Brian J. ^{[1
]}

Bartlett, David J. ^{[1
]}

Mcgarrah, Patrick W. ^{[1
,2
]}

Lewis, Akeem R. ^{[1
,2
]}

Johnson, Derek R. ^{[1
]}

Berberoglu, Kezban ^{[3
]}

Pandey, Mukesh K. ^{[1
]}

Packard, Annie T. ^{[1
]}

Halfdanarson, Thorvardur R. ^{[1
,2
]}

Hruska, Carrie B. ^{[1
]}

Johnson, Geoffrey B. ^{[1
]}

Kendi, Tuba ^{[1
]}

机构：

[1] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA

[2] Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA

[3] Anadolu Med Ctr, Dept Nucl Med, Kocaeli, Turkiye

来源：

RADIOLOGY-IMAGING CANCER | 2023年 / 5卷 / 04期

关键词：

Molecular Imaging; Molecular Imaging-Cancer; Molecular Imag-ing-Clinical Translation; Molecular Imaging-Target Development; PET/CT; SPECT/CT; Radionuclide Therapy; Dosimetry; Oncol-ogy; Radiobiology; RECEPTOR RADIONUCLIDE THERAPY; RESISTANT PROSTATE-CANCER; NEUROENDOCRINE TUMORS; SALVAGE THERAPY; GROWTH-FACTOR; PHASE-I; DOSIMETRY; PARAGANGLIOMA; LU-177-OCTREOTATE; LU-177-DOTATATE;

D O I：

10.1148/rycan.220157

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Theranostics is the combination of two approaches-diagnostics and therapeutics-applied for decades in cancer imaging using radiopharma-ceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administration (FDA) approval of lutetium 177 (177Lu) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE) and 177Lu-prostate-specific membrane antigen vector-based radionuclide therapies. The field of theranostics has imminent po-tential for emerging clinical applications. This article reviews critical areas of active clinical advancement in theranostics, including forthcoming clinical trials advancing FDA-approved and emerging radiopharmaceuticals, approaches to dosimetry calculations, imaging of different radio-nuclide therapies, expanded indications for currently used theranostic agents to treat a broader array of cancers, and emerging ideas in the field.

引用

页数：16

共 94 条

[1]

[Anonymous], STUD EV EFF SAF LUT

[2] Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers A Preliminary Study [J].

Assadi, Majid ;

Rekabpour, Seyed Javad ;

Jafari, Esmail ;

Divband, GhasemAli ;

Nikkholgh, Babak ;

Amini, Hamidreza ;

Kamali, Hassan ;

Ebrahimi, Sakineh ;

Shakibazad, Nader ;

Jokar, Narges ;

Nabipour, Iraj ;

Ahmadzadehfar, Hojjat .

CLINICAL NUCLEAR MEDICINE, 2021, 46 (11) :E523-E530

[3] 177Lu-DOTATATE and177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment [J].

Assadi, Majid ;

Ahmadzadehfar, Hojjat .

WORLD JOURNAL OF NUCLEAR MEDICINE, 2019, 18 (04) :406-408

[4]

Bal C, 2020, J NUCL MED, V61

[5] Radiobiological effects of the alpha emitter Ra-223 on tumor cells [J].

Bannik, Kristina ;

Madas, Balazs ;

Jarzombek, Marco ;

Sutter, Andreas ;

Siemeister, Gerhard ;

Mumberg, Dominik ;

Zitzmann-Kolbe, Sabine .

SCIENTIFIC REPORTS, 2019, 9 (1)

[6] Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma [J].

Bartolomei, Mirco ;

Bodei, Lisa ;

De Cicco, Concetta ;

Grana, Chiara Maria ;

Cremonesi, Marta ;

Botteri, Edoardo ;

Baio, Silvia Melania ;

Arico, Demetrio ;

Sansovini, Maddalena ;

Paganelli, Giovanni .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (09) :1407-1416

[7] Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results [J].

Baum, Richard P. ;

Schuchardt, Christiane ;

Singh, Aviral ;

Chantadisai, Maythinee ;

Robiller, Franz C. ;

Zhang, Jingjing ;

Mueller, Dirk ;

Eismant, Alexander ;

Almaguel, Frankis ;

Zboralski, Dirk ;

Osterkamp, Frank ;

Hoehne, Aileen ;

Reineke, Ulrich ;

Smerling, Christiane ;

Kulkarni, Harshad R. .

JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (03) :415-423

[8] How We Do It: A Multidisciplinary Approach to 177LU DOTATATE Peptide Receptor Radionuclide Therapy [J].

Burkett, Brian J. ;

Dundar, Ayca ;

Young, Jason R. ;

Packard, Annie T. ;

Johnson, Geoffrey B. ;

Halfdanarson, Thorvardur R. ;

Eiring, Rachel A. ;

Gansen, Denise N. ;

Patton, Cynthia M. ;

Kendi, A. Tuba .

RADIOLOGY, 2021, 298 (02) :261-274

[9] Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors [J].

Bushnell, David L. ;

Madsen, Mark T. ;

O'cdorisio, Thomas ;

Menda, Yusuf ;

Muzahir, Saima ;

Ryan, Randi ;

O'dorisio, M. Sue .

EJNMMI RESEARCH, 2014, 4

[10] HISTORY OF THE DISCOVERY AND EARLY USE OF RADIOACTIVE IODINE [J].

CHAPMAN, EM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 250 (15) :2042-2044

← 1 2 3 4 5 6 7 8 9 10 →